טוען...
Rapid emergence of protease inhibitor resistance in hepatitis C virus
Approximately 170 million people worldwide are infected with hepatitis C virus (HCV). Current standard therapy leads to sustained viral elimination in only about 50% of patients treated. Telaprevir, a novel HCV protease inhibitor, has demonstrated substantial antiviral activity in patients with chro...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3033690/ https://ncbi.nlm.nih.gov/pubmed/20445200 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3000544 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|